SCHEMBL24329646

SCHEMBL24329646

CC(C)(C)OC(=O)N1CC=C(c2ccc3c4c(cccc24)C(=O)N3C2CCC(=O)NC2=O)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK4 Q16654 1/20 0.51
▸ DDB1 Q16531 10/20 0.46
▸ CRBN Q96SW2 10/20 0.46
▸ HTR6 P50406 1/20 0.44
▸ BCL2L11 O43521 1/20 0.44
▸ BCL2 P10415 1/20 0.44
▸ MCL1 Q07820 1/20 0.44
▸ JAK1 P23458 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ OPRM1 P35372 1/20 0.41
▸ IKZF3 Q9UKT9 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ BRD4 O60885 2/20 0.41
▸ CNR1 P21554 1/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ WDR77 Q9BQA1 1/20 0.40
▸ GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26621089 0.98 PDK4 (0.49) PDK4DDB1CRBNHTR6BCL2L11
SCHEMBL30273572 0.85 DDB1 (0.43) DDB1CRBNBCL2L11BCL2MCL1
SCHEMBL27091607 0.85 DDB1 (0.49) DDB1CRBNBCL2L11BCL2MCL1
SCHEMBL23250139 0.85 PDK4 (0.60) PDK4DDB1CRBNALDH1A1CHRM2
SCHEMBL29874068 0.85 PDK4 (0.60) PDK4DDB1CRBNALDH1A1CHRM2
SCHEMBL30738793 0.85 DDB1 (0.49) DDB1CRBNBCL2L11BCL2MCL1
SCHEMBL26597812 0.85 CRBN (0.45) DDB1CRBNBCL2L11BCL2MCL1
SCHEMBL30273524 0.84 CRBN (0.46) DDB1CRBNBCL2L11BCL2MCL1
SCHEMBL29584536 0.84 DDB1 (0.47) DDB1CRBNBCL2L11BCL2MCL1
SCHEMBL22533289 0.84 DDB1 (0.47) DDB1CRBNBCL2L11BCL2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 — — US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 — — US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 — — US disclosed
CN-116723839-A Tricyclic heterobifunctional compounds for degrading target proteins C4医药公司 2023-09-08 — — CN disclosed
EP-4228625-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 PDK4 2664/4885DDB1 165/4885CRBN 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback